Moderna has settled related lawsuits that accused it of misusing Alnylam Pharmaceuticals' patented technology in its COVID-19 ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in ...

Even before the change in policies that are being implemented now, vaccines were a difficult business,” Andrew W. Lo, an ...

While mRNA changed the game in vaccines, leveraging the technology to develop treatments has been trickier to navigate.

Speaking at a WIRED event Tuesday, Moderna CEO Stéphane Bancel said he was “encouraged” by the company’s dialogue with the ...

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which ...

Pfizer (PFE) and Moderna (MRNA) reveal trial data showing their updated COVID mRNA vaccines are safe and effective after ...

Moderna shares were down 7.4% Friday—their lowest level since March 2020. The drop brought the drugmaker’s year-to-date slump ...

Shares of COVID-19 vaccine makers are trading lower Friday. Vaccine stocks fell Friday on a Washington Post report that Trump ...

Pfizer and Moderna shares fell after reports said Trump officials plan to link Covid vaccines to child deaths at a key CDC ...

Moderna said the 2025-2026 formula of its Covid-19 vaccine produced a strong immune response against the dominant LP.8.1 variant. The company said a preliminary analysis from a phase four clinical ...

The updated COVID-19 vaccines targeting the LP.8.1 variant have been approved by the FDA. But they may be a lot harder to get ...